



## University of Liverpool

Department of Molecular and Clinical Cancer Medicine,  
Daulby Street  
L69 3GA, Liverpool

[Homepage](#)

## Project leader



**Professor John Neoptolemos**

Phone: +44 151 706 4175

Fax: +44 151 706 5826

[Email](#)



**Dr William Greenhalf**

Phone: +44 151 706 4184

Fax: +44 151 706 5826

[Email](#)

**Dr Eithne Costello**

Phone: +44 151 706 4178

Fax: +44 151 706 5826

[Email](#)



## Project staff



**Dr Taoufik Nedjadi**

Phone: +44 151 706 4191

Fax: +44 151 706 5826

[Email](#)

## Institute presentation

The Liverpool group (ULIV) come from The Department of Molecular and Clinical Cancer Medicine, The NIHR Liverpool Pancreas Biomedical Research Unit (Liverpool PBRU) and The Liverpool Cancer Research UK Centre.

ULIV conducts large Europe-wide pancreatic cancer trials, including the [ESPAC trials](#) of chemotherapy and chemoradiotherapy in the treatment of patients who have undergone surgery and the TeloVac Trial of a vaccine in combination with chemotherapy for advanced pancreatic cancer.

ULIV also co-ordinates the [EUROPAC](#) register which is the world's largest collection of families with Hereditary Pancreatitis and Familial Pancreas Cancer. ULIV is currently working with these families to identify the underlying genetic cause of these diseases. Related work (a Europe-wide study called PANGEN) is attempting to identify how environmental and genetic factors interact to cause pancreatic cancer.

Systematic comparisons of protein expression profiles from highly purified specimens of pancreatic cancer and corresponding normal tissue, and blood from patients and healthy individuals have been undertaken to identify biomarkers. We take biomarkers from such basic laboratory research through to fully auditable analyses, conducted at the level of good clinical laboratory practice. This allows us to use samples from clinical trials to identify biomarkers for

drug response.